Apexigen, Inc., a clinical-stage company focused on developing innovative antibody-based therapeutics for the treatment of cancer with a focus on immuno-oncology, has engaged Ladenburg Thalmann & Co. Inc., to evaluate strategic alternatives for the company with the goal of maximizing stockholder value. Apexigen will implement a corporate restructuring to extend its cash runway as it reviews and explores strategic alternatives. As part of the restructuring, the company plans to reduce its ...